A Two-Part Study of CLE-100 as an Adjunct Therapy in Subjects With Major Depressive Disorder

The Cleo Study is evaluating an oral study medication to see if it may reduce symptoms of depression. The estimated time commitment is 9 weeks and study activities may include surveys, personal health tracking, blood draws, medication, and office visits. There will be a treatment period of 4 weeks, during which you will receive the oral study medication or placebo. You will continue to take your current depression medication during this time

If you qualify and enroll, you will receive all study-related care, including assigned study medication, at no cost, and close monitoring of your depression by an experienced study team. Monetary compensation may be available.

If you are interested in participating, please contact Julianne Origlio at 617-643-2497 or joriglio@mgh.harvard.edu

< Back to Our studies listing